


## VT103

<b>Cat. No.:</b>	HY-134955		
<b>CAS No.:</b>	2290608-13-6		
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>17</sub> F <sub>3</sub> N <sub>4</sub> O <sub>2</sub> S		
<b>Molecular Weight:</b>	410.41		
<b>Target:</b>	YAP		
<b>Pathway:</b>	Stem Cell/Wnt		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (121.83 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	<b>1 mM</b>	2.4366 mL	12.1829 mL	24.3659 mL
	<b>5 mM</b>	0.4873 mL	2.4366 mL	4.8732 mL
	<b>10 mM</b>	0.2437 mL	1.2183 mL	2.4366 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.09 mM); Clear solution			

### BIOLOGICAL ACTIVITY

<b>Description</b>	VT103, an analog of VT101, is an orally active and selective TEAD1 protein palmitoylation inhibitor. VT103 inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation, and disrupts interaction between YAP/TAZ and TEAD. VT103 can be used for the research of cancer <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	TEAD1 Palmitoylation <sup>[1]</sup>
<b>In Vitro</b>	VT103 (HEK293T cells; 3 μM) appears to be TEAD1-selective, as it does not block palmitoylation of TEAD2, TEAD3, or TEAD4. VT103 (NF2-deficient NCI-H226 cells; 3 mmol/L; 4 or 24 hours) selectively disrupts YAP-TEAD1 interaction <sup>[1]</sup> . VT103 results in the disappearance of palmitoylated TEAD1 with a concomitant increase in unpalmitoylated TEAD1 <sup>[1]</sup> . VT103 shows an IC <sub>50</sub> of 1.02 nM in YAP reporter assay <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**VT103 (0.3~10 mg/kg; p.o. once per day) blocks tumor growth even at 0.3 mg/kg<sup>[1]</sup>.Pharmacokinetics of VT103 in mice<sup>[1]</sup>

Dose	IV					PO		
	T1/2 (hours)	Vdss (L/kg)	Cl(mL/min/kg)	AUC 0-24 hours (μg*h/mL)	AUC 0-24 hours (μg*h/mL)	Oral availability (%)	C <sub>max</sub> (ng/mL)	C <sub>24</sub> hours (ng/mL)
7 mg/kg	13.2	4.5	4.7	20.0	14.9	75	896 (1 hour)	340

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCI-H226-tumor bearing mice <sup>[1]</sup>
Dosage:	0.3~10 mg/kg
Administration:	P.o. once per day
Result:	Blocked tumor growth even at 0.3 mg/kg.

**CUSTOMER VALIDATION**

- J Med Chem. 2022 Jun 28.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)**REFERENCES**

[1]. Tang TT, et al. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. Mol Cancer Ther. 2021;20(6):986-998.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA